DEVELOPMENT OF VENTRICLE ASSIST DEVICE (VAD) ACTUATOR

心室辅助装置 (VAD) 执行器的开发

• 批准号: 2863521
• 负责人: NICHOLAS G VITALE
• 金额: $ 9.98万
• 依托单位: FOSTER-MILLER TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-05-15 至 1999-11-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2863521
• 关键词: auxiliary heart prosthesis; biomedical device power system; biomedical equipment development; circulatory assist; clinical biomedical equipment; heart ventricle; medical implant science

The long-term goal of this project is to develop a durable, reliable, second- generation, pulsatile Ventricular Assist Device (VAD), combining a proprietary magscrew actuator with a biolized blood pump. The actuator is similar to the magscrew Total Artificial Heart (TAH) actuator now under development The magscrew offers to the VAD the same benefits of reduced wear, no fatigue, and essentially lossless conversion of rotational motion to translational actuation, as is being demonstrated in the TAH. However, absence of the right-side pumping chamber changes envelope constraints, and permits actuator packaging in an even more optimal form. It also enables the major innovation of this application, the addition of a "magspring" to the actuator. With only one pumping chamber, the return stroke of the actuator can be used to store energy in the magspring, which reduces the loads and energy consumption during the VAD power stroke. This, in turn, enables the use of smaller actuator components, while maintaining or increasing life and reliability. The specific aims are to: I) design magsprings of appropriate size and force characteristics; 2) experimentally validate the magspring calculations; 3) fabricate and test an integrated magscrew and magspring actuator; and 4) lay out the package and define VAD performance with an optimal magscrew/magspring actuator. PROPOSED COMMERCIAL APPLICATIONS:Studies have predicted that there are 35,000 to 70,000 candidates annually for mechanical circulatory support, perhaps 70 to 80% requiring VADs and the remainder justifying the use of a TAH. A sufficiently safe, effective system could have a market as large as 200,000 cases per year, if its use in patients "only"' incapacitated by heart disease was justified. This is the commercial opportunity and social need to be addressed by the proposed research.

该项目的长期目标是开发一种耐用、可靠的第二代脉动式心室辅助装置（VAD），将专有的磁力螺钉致动器与生物化血泵相结合。该致动器类似于目前正在开发中的磁力螺钉全人工心脏（TAH）致动器。磁力螺钉为VAD提供了相同的益处，即减少磨损、无疲劳，以及旋转运动到平移致动的基本无损转换，正如在TAH中所证明的那样。然而，右侧泵送室的缺失改变了包络约束，并且允许以甚至更优化的形式封装致动器。它还实现了该应用的主要创新，即在致动器中添加“磁弹簧”。由于只有一个泵送室，致动器的返回冲程可用于将能量存储在磁弹簧中，这减少了VAD动力冲程期间的负载和能量消耗。这又使得能够使用更小的致动器部件，同时保持或增加寿命和可靠性。具体目标是：1）设计适当尺寸和力特性的磁弹簧; 2）通过实验验证磁弹簧计算; 3）制造和测试集成磁螺钉和磁弹簧致动器;以及4）布置封装并定义具有最佳磁螺钉/磁弹簧致动器的VAD性能。建议的商业应用：研究预测，每年有35，000至70，000名候选人需要机械循环支持，可能有70%至80%需要VAD，其余的则需要使用TAH。一个足够安全、有效的系统每年可以有20万例的市场，如果它在“仅仅”因心脏病丧失能力的患者中使用是合理的。这是商业机会和社会需要解决的拟议研究。

项目成果

In vivo performance and biocompatibility of the MagScrew ventricular assist device.

MagScrew 心室辅助装置的体内性能和生物相容性。

• DOI: 10.1097/01.mat.0000084107.46300.21
• 发表时间: 2003
• 期刊: ASAIO journal (American Society for Artificial Internal Organs : 1992)
• 作者: Schenk,Soren;Weber,Stephan;Luangphakdy,Viviane;Flick,ChristineR;Chen,Ji-Feng;Inoue,Masahiro;KopcakJr,MichaelW;Ootaki,Yoshio;Doi,Kazuyoshi;Dessoffy,Raymond;Hirschman,GordonB;Vitale,NicholasG;ChapmanJr,PeterA;Smith,William
• 通讯作者: Smith,William